{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T06:52:05Z","timestamp":1768546325358,"version":"3.49.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,11,18]]},"DOI":"10.7759\/cureus.11554","type":"journal-article","created":{"date-parts":[[2020,11,18]],"date-time":"2020-11-18T22:19:33Z","timestamp":1605737973000},"source":"Crossref","is-referenced-by-count":3,"title":["Prolonged Glucosuria With Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors: A Case Report and Review of Literature"],"prefix":"10.7759","author":[{"given":"Ankita","family":"Aggarwal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anubhav","family":"Jain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonali","family":"Sachdeva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zain I","family":"Kulairi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman B","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, et al.. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015, 373:2117-2128. 10.1056\/nejmoa1504720","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal B","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW, et al.. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017, 377:644-657. 10.1056\/nejmoa1611925","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott SD","year":"2019","unstructured":"Wiviott SD, Raz I, Bonaca MP, et al.. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019, 380:347-357. 10.1056\/NEJMoa1812389","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic V","year":"2019","unstructured":"Perkovic V, Jardine MJ, Neal B, et al.. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019, 380:2295-2306. 10.1056\/NEJMoa1811744","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.2337\/dc15-1251","article-title":"Diabetic ketoacidosis and related events in the canagliflozin type 2 diabetes clinical program","volume":"38","author":"Erondu N","year":"2015","unstructured":"Erondu N, Desai M, Ways K, Meininger G. Diabetic ketoacidosis and related events in the canagliflozin type 2 diabetes clinical program. Diabetes Care. 2015, 38:1680-1686. 10.2337\/dc15-1251","journal-title":"Diabetes Care"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1097\/MAJ.0b013e31827424ab","article-title":"Comparison of diabetic ketoacidosis in patients with type-1 and type-2 diabetes mellitus","volume":"345","author":"Barski L","year":"2013","unstructured":"Barski L, Nevzorov R, Jotkowitz A, et al.. Comparison of diabetic ketoacidosis in patients with type-1 and type-2 diabetes mellitus. Am J Med Sci. 2013, 345:326-330. 10.1097\/MAJ.0b013e31827424ab","journal-title":"Am J Med Sci"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1530\/EDM-17-0081","article-title":"Euglycemic diabetic ketoacidosis: a diagnostic and therapeutic dilemma","volume":"2017","author":"Rawla P","year":"2017","unstructured":"Rawla P, Vellipuram AR, Bandaru SS, Pradeep Raj J. Euglycemic diabetic ketoacidosis: a diagnostic and therapeutic dilemma. Endocrinol Diabetes Metab Case Rep. 2017, 2017:17-0081. 10.1530\/EDM-17-0081","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1881","article-title":"SGLT2 inhibitors: a systematic review of diabetic ketoacidosis and related risk factors in the primary literature","volume":"37","author":"Burke KR","year":"2017","unstructured":"Burke KR, Schumacher CA, Harpe SE. SGLT2 inhibitors: a systematic review of diabetic ketoacidosis and related risk factors in the primary literature. Pharmacotherapy. 2017, 37:187-194. 10.1002\/phar.1881","journal-title":"Pharmacotherapy"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-015-0285-z","article-title":"Clinical pharmacokinetic, pharmacodynamic, and drug-drug interaction profile of canagliflozin, a sodium-glucose co-transporter 2 inhibitor","volume":"54","author":"Devineni D","year":"2015","unstructured":"Devineni D, Polidori D. Clinical pharmacokinetic, pharmacodynamic, and drug-drug interaction profile of canagliflozin, a sodium-glucose co-transporter 2 inhibitor. Clin Pharmacokinet. 2015, 54:1027-1041. 10.1007\/s40262-015-0285-z","journal-title":"Clin Pharmacokinet"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1177\/2324709617710040","article-title":"Prolonged ketosis in a patient with euglycemic diabetic ketoacidosis secondary to dapagliflozin","volume":"5","author":"Pujara S","year":"2017","unstructured":"Pujara S, Ioachimescu A. Prolonged ketosis in a patient with euglycemic diabetic ketoacidosis secondary to dapagliflozin. J Investig Med High Impact Case Rep. 2017, 5:2324709617710040. 10.1177\/2324709617710040","journal-title":"J Investig Med High Impact Case Rep"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.xkme.2019.12.006","article-title":"SGLT2 inhibitor-induced euglycemic diabetic ketoacidosis: a case report","volume":"2","author":"Wang KM","year":"2020","unstructured":"Wang KM, Isom RT. SGLT2 inhibitor-induced euglycemic diabetic ketoacidosis: a case report. Kidney Med. 2020, 2:218-221. 10.1016\/j.xkme.2019.12.006","journal-title":"Kidney Med"},{"key":"ref12","unstructured":"INVOKANA (canagliflozin) tablets. (2013). Accessed. October 6, 2020: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/204042s026lbl.pdf."},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.56.7501","article-title":"Euglycemic diabetic ketoacidosis with persistent diuresis treated with canagliflozin","volume":"56","author":"Adachi J","year":"2017","unstructured":"Adachi J, Inaba Y, Maki C. Euglycemic diabetic ketoacidosis with persistent diuresis treated with canagliflozin. Intern Med. 2017, 56:187-190. 10.2169\/internalmedicine.56.7501","journal-title":"Intern Med"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1097\/00007691-200502000-00014","article-title":"The pH dependency of the binding of drugs to plasma proteins in man","volume":"27","author":"Hinderling PH","year":"2005","unstructured":"Hinderling PH, Hartmann D. The pH dependency of the binding of drugs to plasma proteins in man. Ther Drug Monit. 2005, 27:71-85. 10.1097\/00007691-200502000-00014","journal-title":"Ther Drug Monit"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.2337\/dc15-1380","article-title":"Euglycemic diabetic ketoacidosis: a predictable, detectable, and preventable safety concern with SGLT2 inhibitors","volume":"38","author":"Rosenstock J","year":"2015","unstructured":"Rosenstock J, Ferrannini E. Euglycemic diabetic ketoacidosis: a predictable, detectable, and preventable safety concern with SGLT2 inhibitors. Diabetes Care. 2015, 38:1638-1642. 10.2337\/dc15-1380","journal-title":"Diabetes Care"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.2337\/db12-0052","article-title":"Why do SGLT2 inhibitors inhibit only 30-50% of renal glucose reabsorption in humans?","volume":"61","author":"Liu JJ","year":"2012","unstructured":"Liu JJ, Lee T, DeFronzo RA. Why do SGLT2 inhibitors inhibit only 30-50% of renal glucose reabsorption in humans?. Diabetes. 2012, 61:2199-204. 10.2337\/db12-0052","journal-title":"Diabetes"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1186\/s13098-020-0516-9","article-title":"Impact of sodium-glucose cotransporter 2 inhibitors on renal function in participants with type 2 diabetes and chronic kidney disease with normoalbuminuria","volume":"12","author":"Nakamura A","year":"2020","unstructured":"Nakamura A, Miyoshi H, Kameda H, Yamashita K, Kurihara Y. Impact of sodium-glucose cotransporter 2 inhibitors on renal function in participants with type 2 diabetes and chronic kidney disease with normoalbuminuria. Diabetol Metab Syndr. 2020, 12:4. 10.1186\/s13098-020-0516-9","journal-title":"Diabetol Metab Syndr"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2014.02.022","article-title":"Effects of hydrochlorothiazide on the pharmacokinetics, pharmacodynamics, and tolerability of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in healthy participants","volume":"36","author":"Devineni D","year":"2014","unstructured":"Devineni D, Vaccaro N, Polidori D, Rusch S, Wajs E. Effects of hydrochlorothiazide on the pharmacokinetics, pharmacodynamics, and tolerability of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in healthy participants. Clin Ther. 2014, 36:698-710. 10.1016\/j.clinthera.2014.02.022","journal-title":"Clin Ther"},{"key":"ref19","unstructured":"FDA revises labels of SGLT2 inhibitors for diabetes to include warnings about too much acid in the blood and serious urinary tract infections. (2020). Accessed. October 7, 2020: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-revises-labels-sglt2-inhibitors-diabetes-include-warnings-...."},{"key":"ref20","article-title":"Perioperative management of sodium-glucose cotransporter-2 inhibitors: importance of a nuanced approach","volume":"46","author":"Nanjappa N","year":"2018","unstructured":"Nanjappa N, Jesudason D, Thiruvenkatarajan V, Meyer EJ. Perioperative management of sodium-glucose cotransporter-2 inhibitors: importance of a nuanced approach. Anaesth Intensive Care. 2018, 46:424-425.","journal-title":"Anaesth Intensive Care"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/43610-prolonged-glucosuria-with-sodium-glucose-cotransporter-2-sglt2-inhibitors-a-case-report-and-review-of-literature","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:29:44Z","timestamp":1707506984000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/43610-prolonged-glucosuria-with-sodium-glucose-cotransporter-2-sglt2-inhibitors-a-case-report-and-review-of-literature"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,18]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.11554","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11,18]]}}}